FDA's Sklamberg promoted to director of CDER's Office of Compliance

Howard Sklamberg, who has been the FDA deputy associate commissioner for regulatory affairs in the Office of Regulatory Affairs (ORA) since July 2011, is stepping up to become director of Center for Drug Evaluation and Research's Office of Compliance. He replaces Lisa Bernstein, who has been acting director since August 2011. Bernstein will return to her former role as deputy director. The switch will occur Jan. 14, according to an FDA memo that appears in Pharma Manufacturing. The memo says Bernstein will continue to work on the recent meningitis outbreak tied to steroid drugs made at New England Compounding Center that have led to 510 infections and 36 deaths. Sklamberg also has been involved in that probe, the memo points out. A former federal prosecutor with a degree from Harvard Law, Sklamberg was involved in issues related to counterfeit drugs, drug shortages and the inspections of Johnson & Johnson's ($JNJ) McNeil Consumer Healthcare which last year signed a consent decree with the FDA after it had to recall and destroy tens of millions of consumer products for a laundry list of manufacturing problems. Letter | More

Suggested Articles

Researchers scoured the database where pharma companies disclose payments made to physicians and discovered a troubling trend.

Just a few months after playing a pivotal role in Sanofi’s Bioverativ buy, Alex Denner has set his sights on Ironwood.

Clovis' new approval will boost Rubraca in recurrent ovarian cancer, but because of its competitors' head start, the race will be tough.